Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on June 9, 2022. The report details the closing and final results of a previously announced rights offering.
Key Financial Metrics and Capital Structure
- Gross Proceeds: The Company received aggregate gross proceeds of $15 million from the rights offering.
- Units Sold: Eligible stockholders subscribed to purchase 7,317,072 units.
- Offering Price: Units were sold at a price of $2.05 per unit.
- Unit Composition: Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05.
- Outstanding Shares: Following the issuance of 7,317,072 shares from the offering (excluding shares underlying the warrants), the Company has 37,119,352 shares of common stock issued and outstanding.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of $15 million in gross capital resulting from the successful closing of the rights offering.
Outlook and Management Commentary
Management announced the closing of the offering via a press release (Exhibit 99.1). The filing does not contain specific forward-looking guidance, risk factors, or commentary on future operational outlook beyond the completion of this capital raise.
Investor Verification Checklist
- Verify the final number of shares outstanding (37,119,352) excludes the shares underlying the warrants issued in the offering.
- Confirm the exercise price of the warrants ($2.05) and their expiration terms in the full press release (Exhibit 99.1).
- Review the Company's most recent 10-Q or 10-K for current liquidity, cash burn rate, and debt obligations, as this 8-K does not contain those figures.
- Assess the dilution impact of the 7,317,072 new shares on existing shareholders.